Vitamin K Antagonists (Warfarin) are the Preferred Long-Term Anticoagulant After Heparin
For most patients transitioning from heparin, vitamin K antagonists (VKAs) such as warfarin remain the standard long-term anticoagulant, with target INR 2.0-3.0. 1 However, the optimal choice depends critically on specific patient characteristics, particularly cancer status and bleeding risk.
General Population (Non-Cancer Patients)
For patients with venous thromboembolism (VTE) without cancer:
- Start warfarin on the same day as heparin initiation (typically day 1-3 of hospitalization) 1
- Continue heparin for minimum 5 days AND until INR is 2.0-3.0 for at least 2 consecutive days before stopping heparin 1
- Initial warfarin dosing: 5 mg for older patients (>60 years) or those at bleeding risk; 7.5-10 mg for younger, healthy outpatients 1
Alternative: Direct Oral Anticoagulants (DOACs) are increasingly preferred over warfarin in non-cancer patients due to superior convenience and comparable efficacy 2. The 2016 CHEST guidelines suggest dabigatran, rivaroxaban, apixaban, or edoxaban over VKA therapy (Grade 2B) 2. These agents eliminate the need for INR monitoring and have fewer drug-food interactions.
Cancer Patients (Critical Exception)
For cancer-associated thrombosis, low-molecular-weight heparin (LMWH) is superior to warfarin and should be continued as monotherapy for at least 6 months 1, 3, 4, 5. This represents a fundamental departure from standard practice:
- Dalteparin regimen: 200 U/kg once daily for first month, then 150 U/kg daily 3, 5
- Enoxaparin regimen: 1.5 mg/kg once daily 5
- Continue LMWH as long as cancer is active (metastatic disease, ongoing chemotherapy) 3, 4
The rationale: Cancer patients on warfarin experience both higher VTE recurrence rates AND higher bleeding complications compared to LMWH 3. Drug interactions with chemotherapy, malnutrition, and liver dysfunction cause dangerous INR fluctuations 3.
Specific Clinical Scenarios
Severe Renal Dysfunction (CrCl <30 mL/min)
- Unfractionated heparin (UFH) with aPTT monitoring (target 1.5-2.5 times normal) is preferred over LMWH 1
- Warfarin remains appropriate for long-term therapy after initial UFH 1
- Avoid fondaparinux (contraindicated if CrCl <20 mL/min) 1
High Bleeding Risk
- UFH is preferred initially due to short half-life and reversibility with protamine 1
- Transition to warfarin with careful INR monitoring (target 2.0-3.0, never higher) 1
Heparin-Induced Thrombocytopenia (HIT)
If HIT develops during heparin therapy:
- Immediately switch to argatroban or lepirudin (Grade 1C) 6
- Do NOT start warfarin until platelets recover to ≥150 × 10⁹/L 6
- When starting warfarin, use low doses (maximum 5 mg) and overlap with non-heparin anticoagulant for minimum 5 days 6
Duration of Therapy
Minimum 3 months for all VTE 1, 2:
- Surgery-provoked VTE: Stop at 3 months 2
- Unprovoked VTE with low-moderate bleeding risk: Consider indefinite therapy 1, 2
- Cancer-associated VTE: Continue indefinitely while cancer active 3, 4
Common Pitfalls to Avoid
- Never stop heparin before achieving therapeutic INR for 2 consecutive days - this creates a dangerous anticoagulation gap 1
- Never use warfarin as first-line in cancer patients - LMWH is definitively superior 3, 4, 5
- Never start warfarin during acute HIT - risk of venous limb gangrene 6
- Never use LMWH in severe renal failure without anti-Xa monitoring - unpredictable accumulation 1
Practical Transition Protocol
Day 1-3: Start warfarin 5 mg (or 7.5-10 mg if young/healthy) alongside therapeutic heparin
Day 5+: Check INR daily
When INR 2.0-3.0 × 2 consecutive days: Stop heparin, continue warfarin
Ongoing: Target INR 2.0-3.0 with regular monitoring 1
The landscape is shifting toward DOACs in non-cancer patients due to superior convenience and safety profiles 2, but warfarin remains highly effective when properly managed and is often preferred due to cost considerations and reversibility with vitamin K.